Results 1 to 10 of about 24,911 (203)

Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review [PDF]

Annals of Hematology
Decitabine, including its new oral formulation (decitabine-cedazuridine, DEC-C), is commonly used in AML and MDS, particularly in older or unfit patients.
Laura Cannella, Adriano Venditti, Raffaele Palmieri, Serena Puglia, Mario Luppi, Massimo Breccia, Fabio Efficace   +6 more
doaj   +2 more sources

Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia [PDF]

Frontiers in Pharmacology
BackgroundThe objective of this real-world cohort study was to evaluate the efficacy and safety of decitabine versus conventional chemotherapy in the maintenance therapy (MT) of patients with acute myeloid leukemia (AML).MethodsData were collected from ...
Zhi-Feng Wei, Zhi-Feng Wei, Jia-Qi Yan, Jia-Qi Yan, Ye-Hui Tan, Ye-Hui Tan, Hai Lin, Hai Lin, Qiu-Ju Liu, Qiu-Ju Liu, Xiao-Liang Liu, Xiao-Liang Liu, Long Su, Long Su, Su-Jun Gao, Su-Jun Gao   +15 more
doaj   +2 more sources

Decitabine in the treatment of acute myeloid leukemia in elderly patients [PDF]

Cancer Management and Research, 2014
Priya Malik, Amanda F CashenWashington University School of Medicine, St Louis, MO, USAAbstract: The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating
Malik P, Cashen AF
doaj   +4 more sources

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia

Clinical Case Reports (discontinued), 2020
A case of an early‐relapsed high‐risk T‐ALL with high BCL‐2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. We suggest decitabine and venetoclax should be synergistic in BCL2‐positive ALL.
Emanuele Cencini, Anna Sicuranza, Alessandro Gozzetti   +2 more
exaly   +2 more sources

Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in β-thalassemia/HbE erythroid progenitor cells [PDF]

Molecular Medicine
Background Fetal hemoglobin (HbF; α2γ2) induction is a well-established approach for β-hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia.
Tiwaporn Nualkaew, Phitchapa Pongpaksupasin, Thongperm Munkongdee, Nattrika Buasuwan, Kittiphong Paiboonsukwong, Orapan Sripichai, James Douglas Engel, Suradej Hongeng, Suthat Fucharoen, Natee Jearawiriyapaisarn   +9 more
doaj   +2 more sources

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

Frontiers in Cell and Developmental Biology, 2021
BackgroundCD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response.
Xiang Li, Xiang Li, Liang Dong, Jiejie Liu, Chunmeng Wang, Yan Zhang, Qian Mei, Weidong Han, Ping Xie, Jing Nie   +9 more
doaj   +1 more source

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia

Clinical Epigenetics, 2023
Background Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21)
Shujiao He, Yan Li, Xuanren Shi, Lei Wang, Diya Cai, Jingfeng Zhou, Li Yu   +6 more
doaj   +1 more source

Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. [PDF]

PLoS ONE, 2014
Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells ...
Naoya Uchida, Matthew M Hsieh, Charlotte Platner, Yogen Saunthararajah, John F Tisdale   +4 more
doaj   +1 more source

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

Cardio-Oncology, 2023
Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML).
Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga, Kristin L. Koenig   +5 more
doaj   +1 more source

Absence of early platelet increment in healthy mice during decitabine treatment

Scientific Reports, 2022
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on
Juliane Baumann, Markus Spindler, Yannick Throm, Michael Lübbert, Markus Bender   +4 more
doaj   +1 more source